The Food and Drug Administration told Merck & amp ; Co. that it requires further safety and efficacy data before it will approve its successor drug to now defunct pain reliever Vioxx, the pharmaceutical maker announced Friday.
Merck and federal officials should have withdrawn the painkiller Vioxx from the market as early as 2000 because studies of the drug had clearly shown that it doubled the risk of heart attacks among users, according to a study released Thursday by The Lancet, a British medical journal.
US pharmaceutical giant Merck on Friday disputed the conclusion of the British medical weekly The
